|
Aberrant signaling in acute myeloid leukemia
|
5R01CA204396-03
|
$459,674
|
KENTSIS, ALEX
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Beyond apoptosis, Bcl-xL in tumor metastasis
|
5R01CA204916-02
|
$390,659
|
DU, YI-CHIEH NANCY
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
CAR-T cell control through orthogonal antibody-based switches
|
5R01CA208398-03
|
$412,234
|
YOUNG, TRAVIS
|
CALIFORNIA INSTITUTE/BIOMEDICAL RESEARCH
|
|
CHARACTERIZATION OF THE MOLECULAR INTERPLAY BETWEEN HOXA9 AND OGT IN ACUTE LEUKEMIA
|
5R01CA187903-04
|
$354,563
|
RUAL, JEAN-FRANCOIS
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Determining the role of DNMT-interacting RNAs in myeloid disorders
|
5R00CA188595-04
|
$249,000
|
DI RUSCIO, ANNALISA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Developing novel combination therapies for pancreatic cancer
|
5R01CA208272-02
|
$339,694
|
YOON, KARINA
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Development and Preclinical Applications of Pancreatic Adenocarcinoma Models
|
ZIA BC 011739
|
$1,126,602
|
Sharan, Shyam
|
CCR (NCI)
|
|
Development of novel selective Rac inhibitors for refractory leukemias
|
5R01CA202756-03
|
$560,804
|
WILLIAMS, DAVID
|
BOSTON CHILDREN'S HOSPITAL
|
|
Development of novel therapies for megakaryocytic malignancies
|
5R50CA211534-03
|
$130,753
|
WEN, QIANG
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
Direct coregulation of Notch1 by Zmiz1 in T-cell leukemia
|
5R01CA196604-04
|
$354,563
|
CHIANG, MARK
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML
|
5R01CA194094-04
|
$358,560
|
LI, HONG-YU
|
UNIV OF ARKANSAS FOR MED SCIS
|
|
Drug resistant pathways in relapsed acute lymphoblastic leukemia (ALL)
|
5R01CA140729-08
|
$461,060
|
CARROLL, WILLIAM
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
Dynamic requirements of Ras signaling during cancer
|
5R01CA123031-10
|
$341,774
|
COUNTER, CHRISTOPHER
|
DUKE UNIVERSITY
|
|
Engineering chimeric antigen receptors with VLR-mediated cancer recognition in CD5 edited gamma delta T cells
|
5F31CA221002-02
|
$44,524
|
FLEISCHER, LAUREN
|
EMORY UNIVERSITY
|
|
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19
|
5P01CA214278-02
|
$2,804,200
|
JUNE, CARL
|
UNIVERSITY OF PENNSYLVANIA
|
|
Epigenetic Regulation in High-Risk Leukemia
|
5F30CA221109-02
|
$49,524
|
PAYNE, JONATHON
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
Evaluation of Bruton's Tyrosine Kinase and p110 delta in Mutant Shp2-Induced JMML
|
5F30CA210518-03
|
$49,524
|
DENG, LISA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Exercise and QUality diet After Leukemia
|
5R01CA187397-05
|
$613,996
|
TONOREZOS, EMILY
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Exosomes in Cancer Therapy
|
5R01CA213233-02
|
$384,147
|
KALLURI, RAGHU
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Exploiting the Context-Dependence of Notch to Develop Safer T-ALL therapy
|
1F30CA228228-01
|
$36,023
|
GORMLEY, ANNA
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Exploring oncogenic translation programs in cancer
|
5R01CA207217-03
|
$406,648
|
WENDEL, HANS-GUIDO
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Extent and Significance of Bacterial DNA Integrations in the Human Cancer Genome
|
5R01CA206188-04
|
$1
|
HOTOPP, JULIE
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
Glutaminase Inhibitor Drug Discovery and Nanoparticle-Based Delivery for Pancreatic Cancer Therapy
|
5R01CA193895-03
|
$425,618
|
SLUSHER, BARBARA
|
JOHNS HOPKINS UNIVERSITY
|
|
Hematopoietic Chimerism after Stem Cell Allografts
|
5P01CA078902-20
|
$892,086
|
STORB, RAINER
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Identification of genomic regulatory elements in pancreas cells
|
ZIA BC 011798
|
$800,611
|
Arda, Hatice
|
CCR (NCI)
|
|
Identification of microRNA variants associated with acute lymphoblastic leukemia
|
5R03CA219724-02
|
$83,750
|
DEWAN, ANDREW
|
YALE UNIVERSITY
|
|
IGF::OT::IGF IGF::OF::IGF- PHASE III TRIAL OF CARBON ION THERAPY
|
261201500022C
|
$462,158
|
GUHA, CHANDAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Integration of gene expression patterns, fusions, mutations, cytogenetics and other clinical variables for subtyping leukemias and targeting therapies
|
5R50CA211542-03
|
$154,500
|
HARVEY, RICHARD
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
|
Integrative Molecular Epidemiology of Neurocognitive Outcomes in Acute Lymphoblastic Leukemia
|
1K07CA218362-01A1
|
$166,043
|
BROWN, AUSTIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Integrative Molecular Profiling of Human Pancreatic Cancer
|
ZIA BC 011162
|
$459,509
|
Hussain, S. Perwez
|
CCR (NCI)
|
|
Investigating the Role of Autophagy in Pancreatic Cancer Radiation Resistance
|
5R01CA157490-08
|
$402,563
|
KIMMELMAN, ALEC
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
JAK1 Signaling in Pancreatic Cancer Initiation and Progression
|
5R01CA202917-02
|
$117,233
|
WAGNER, KAY-UWE
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
K-Ras mutant-specific vulnerabilities for novel pancreatic cancer therapies
|
5F32CA200313-03
|
$30,587
|
HOBBS, GUY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
KIR-FAVORABLE HAPLOIDENTICAL TRANSPLANTATION IN CHILDREN
|
5R01CA181050-05
|
$291,828
|
PULSIPHER, MICHAEL
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Material Hardship as a Targetable Measure of Poverty in Pediatric Cancer
|
5K07CA211847-03
|
$133,475
|
BONA, KIRA
|
DANA-FARBER CANCER INST
|
|
Mechanism(s) of TAL1-and NOTCH1-mediated Leukemogenesis
|
5R01CA096899-13
|
$358,031
|
KELLIHER, MICHELLE
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
|
5R35CA210064-03
|
$1,046,441
|
LOOK, A
|
DANA-FARBER CANCER INST
|
|
Mechanisms of regulation by RNA in acute myeloid leukemia
|
5R35CA197697-04
|
$1,042,185
|
TENEN, DANIEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Mechanisms, Prevention and Treatment of Chronic Graft-vs.-Host Disease
|
5P01CA142106-14
|
$1,630,446
|
CUTLER, COREY
|
DANA-FARBER CANCER INST
|
|
Mesothelin-targeted immunotoxins in Pancreatic Cancer
|
ZIA BC 011652
|
$700,006
|
Alewine, Christine
|
CCR (NCI)
|
|
Metabolic rewiring by oncogenic BRAF V600E links ketogenesis pathway to BRAF-MEK1 signaling
|
5R01CA140515-09
|
$373,250
|
CHEN, JING
|
EMORY UNIVERSITY
|
|
MLL Family Histone Methyltransferases in Myeloid Leukemia
|
1R01CA224436-01A1
|
$424,527
|
ERNST, PATRICIA
|
UNIVERSITY OF COLORADO DENVER
|
|
Molecular Imaging of Cachexia in Pancreatic Cancer
|
5R01CA193365-03
|
$194,400
|
BHUJWALLA, ZAVER
|
JOHNS HOPKINS UNIVERSITY
|
|
Molecular Interactions of APOBEC3 Enzymes with the Cancer Genome
|
5K08CA212299-03
|
$148,742
|
GREEN, ABBY
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Molecular strategies for early detection and targeting of cancer
|
5R35CA197699-04
|
$898,918
|
REYA, TANNISHTHA
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
Mutations of Chromatin and its Modifying Machineries in Malignancies
|
5R35CA197569-04
|
$919,663
|
SHILATIFARD, ALI
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
Nanoparticle mediated microenvironmental targeting of CCL3 signaling for the treatment of acute myelogenous leukemia
|
1F31CA228391-01
|
$42,418
|
ACKUN-FARMMER, MARIAN
|
UNIVERSITY OF ROCHESTER
|
|
Novel anthraquinones induce apoptosis by disruption MDM2/MDM4 interactions
|
5R01CA180519-05
|
$442,311
|
WANG, BINGHE
|
GEORGIA STATE UNIVERSITY
|
|
Novel Strategies to Eliminate Resistance to B-cell Receptor Inhibitor Therapy in Lymphoid Malignancies
|
5K23CA212271-03
|
$180,360
|
STEPHENS, DEBORAH
|
UNIVERSITY OF UTAH
|
|
Novel Theranostics for Pancreatic Cancer
|
5R01CA174861-05
|
$319,031
|
DAVYDOVA, JULIA
|
UNIVERSITY OF MINNESOTA
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|